<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20041014144153+02'00'</creation_date><modification_date>D:20041014144211+02'00'</modification_date><initial_authorization>True</initial_authorization><pdf_file>EU-1-04-286_h_a_dec_0.pdf</pdf_file></head><body><section><header>en</header><p>commission of the european communities</p><p>brussels, 13-x-2004 c(2004)4056 
 not for publication</p></section><section><header>commission decision of 13-x-2004 
 granting the marketing authorization for the orphan medicinal product for human 
 use &quot;wilzin - zinc acetate dihydrate&quot; under council regulation (eec) no 2309/93 
 (text with eea relevance)</header><p>only the french text is authentic</p></section><section><header>en  
   en</header></section><section><header>en  
   en</header></section><section><header>commission decision of 13-x-2004 
 granting the marketing authorization for the orphan medicinal product for human 
 use &quot;wilzin - zinc acetate dihydrate&quot; under council regulation (eec) no 2309/93 
 (text with eea relevance)</header><p>the commission of the european communities, having regard to the treaty establishing the european community,</p><p>
 having regard to council regulation (eec) no 2309/93 of 22 july 1993 laying down 
 community procedures for the authorization and supervision of medicinal products for 
 human and veterinary use and establishing a european agency for the evaluation of 
 medicinal products
 1, as amended by commission regulation (ec) no 649/982, and in particular article 10(2) thereof, 
 having regard to regulation (ec) no 141/2000 of the european parliament and of the 
 council of 16 december 1999 on orphan medicinal products
 3, having regard to the application submitted by orphan europe sarl on 24 march 2003 
 under article 4(1) of regulation (eec) no 2309/93, 
 having regard to the opinion of the european medicines agency formulated by the 
 committee for medicinal products for human use on 23 june 2004, 
 whereas: 
 (1)</p><p>commission decision c(2001)2052 of 31 july 2001 designated &quot;zinc acetate 
 dihydrate&quot; as an orphan medicinal product. 
 (2)</p><p>the orphan medicinal product &quot;wilzin - zinc acetate dihydrate&quot; complies with the 
 requirements set out in directive 2001/83/ec of the european parliament and of 
 the council of 6 november 2001 on the community code relating to medicinal 
 products for human use
 4 as amended by directive 2002/98/ec5 and by directive 2003/63/ec
 6. (3)</p><p>it is therefore appropriate to authorise its placing on the market.</p><p>
 1 oj l 214, 24. 8. 1993, p. 1. 2 oj l 88, 24.3.1998, p. 7. 3 oj l 18, 22.1.2000, p. 1. 4 oj l 311, 28.11.2001, p. 67. 5 oj l 33, 8.2.2003, p. 30. 6 oj l 159, 27.6.2003, p. 46.</p></section><section><header>en  
   en</header><p>(4) the measures provided for in this decision are in accordance with the opinion of 
 the standing committee on medicinal products for human use, 
 has adopted this decision: 
 article 1 the marketing authorisation referred to in article 3 of regulation (eec) no 2309/93 is hereby granted for the orphan medicinal product &quot;wilzin - zinc acetate dihydrate&quot;, 
 whose characteristics are summarised in annex i hereto. this orphan medicinal product 
 is registered in the community register of medicinal products under nos: 
 eu/1/04/286/001 
 wilzin-25 mg-hard capsule-oral use-bottle (hdpe)-250 capsules 
 eu/1/04/286/002 
 wilzin-50 mg-hard capsule-oral use-bottle (hdpe)-250 capsules 
 article 2 the marketing authorization concerning the medicinal product referred to in article 1 shall be subject to compliance with all the conditions, particularly those relating to 
 manufacture and importation, control and issue referred to in annex ii. 
 article 3 the labelling and package leaflet concerning the orphan medicinal product referred to in article 1 shall conform to annex iii. 
 article 4 the period of validity of the authorization issued shall be five years from the date of notification of this decision.</p><p>
 article 5 this decision is addressed to orphan europe sarl, immeuble “le guillaumet”f-92046 paris-la-défense - france. 
 done at brussels, 13-x-2004 
 for the commission olli rehn</p><p>
 member of the commission</p></section></body></xml>